Miruvor
Sign up
The short answer

What studies of Atenolol (Tenormin) found

2papers on Atenolol (Tenormin)
1 (few people)person in 1 study testing Atenolol (Tenormin) alone
0randomised trials, the strongest kind of study

At a glance, by condition

Both together: C Might help, very uncertain

Based on the strongest evidence, studies with no comparison group (very low certainty): 4 findings, all C.

6 outcomes rated · see each below

How we got this

Each condition’s headline comes from its graded findings (one for each outcome and kind of study) rated with the highest certainty: the grade most of them share; a tie goes to the finding with the most people, then the most studies, then the outcome’s name. It sums up the grades below, and conditions are never combined.

What this means: Atenolol (Tenormin) might help some people with long COVID and ME/CFS studied together, but research can’t show it yet. If you’re thinking about it, talk it through with a doctor who knows ME/CFS or long COVID.

Ask about this treatment

Sign up free to read the rest of what studies found.

You’ll see the full picture: how each symptom fared, every grade with its reasons, side effects and all 2 papers.

The grades, in plain words

Each outcome gets a direction, a certainty and a letter read from the two. Certainty is judged with GRADE, the method Cochrane and WHO use.

  1. A
    HelpsImprovement, high certainty
    Probably helpsImprovement, moderate certainty
  2. B
    May helpImprovement, low certainty
  3. Atenolol (Tenormin) · Both together is hereC
    Might help, very uncertainImprovement, very low certainty
    Mixed resultsStudies disagree
  4. D
    Little or no differenceStudies found little or no difference
  5. F
    HarmsIt made things worse

By symptom and daily life

Both together

Symptoms

Autonomic symptoms1 study · 1 (few people) person took Atenolol (Tenormin) Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (1 in all); not all results were tested against chance.

Studies with no comparison group1 in the study · over 30 months (few people)

Autonomic symptoms improved.

The evidence is very uncertain about the effect of atenolol (Tenormin) on autonomic symptoms in ME/CFS or long COVID. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (1 in all)
  • Not all results were tested against chance
See the 1 study
  1. A Case Study of Successful Application of the Principles of ME/CFS Care to an Individual with Long COVID. (2023)

    People in the study
    1 in the study
    Dose
    —
    Outcome
    peak heart rate when walking on cromolyn
    Effect
    better (not tested)
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Pain1 study · 1 (few people) person took Atenolol (Tenormin) Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (1 in all); not all results were tested against chance.

Studies with no comparison group1 in the study · over 30 months (few people)

Pain improved.

The evidence is very uncertain about the effect of atenolol (Tenormin) on pain in ME/CFS or long COVID. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (1 in all)
  • Not all results were tested against chance
See the 1 study
  1. A Case Study of Successful Application of the Principles of ME/CFS Care to an Individual with Long COVID. (2023)

    People in the study
    1 in the study
    Dose
    —
    Outcome
    remaining symptoms at one year
    Effect
    better (not tested)
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Cognition (brain fog)1 study · 1 (few people) person took Atenolol (Tenormin) Uncertain –
Very low certainty

Why this grade: Uncertain, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (1 in all); not all results were tested against chance; one study saw it get worse, without a test against chance.

Studies with no comparison group1 in the study · over 30 months (few people)

Too little to say about cognition (brain fog).

Too little to say: cognition (brain fog) got worse in one study, but the change wasn't tested against chance. Uncertain · very low certainty –

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (1 in all)
  • Not all results were tested against chance
  • One study saw it get worse, without a test against chance
See the 1 study
  1. A Case Study of Successful Application of the Principles of ME/CFS Care to an Individual with Long COVID. (2023)

    People in the study
    1 in the study
    Dose
    —
    Outcome
    fatigue and cognitive dysfunction on stopping fexofenadine and famotidine
    Effect
    worse (not tested)
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Fatigue1 study · 1 (few people) person took Atenolol (Tenormin) Uncertain –
Very low certainty

Why this grade: Uncertain, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (1 in all); not all results were tested against chance; one study saw it get worse, without a test against chance.

Studies with no comparison group1 in the study · over 30 months (few people)

Too little to say about fatigue.

Too little to say: fatigue got worse in one study, but the change wasn't tested against chance. Uncertain · very low certainty –

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (1 in all)
  • Not all results were tested against chance
  • One study saw it get worse, without a test against chance
See the 1 study
  1. A Case Study of Successful Application of the Principles of ME/CFS Care to an Individual with Long COVID. (2023)

    People in the study
    1 in the study
    Dose
    —
    Outcome
    fatigue and cognitive dysfunction on stopping fexofenadine and famotidine
    Effect
    worse (not tested)
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I

Daily life and health overall

Daily functioning1 study · 1 (few people) person took Atenolol (Tenormin) Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (1 in all); not all results were tested against chance.

Studies with no comparison group1 in the study · over 30 months (few people)

Daily functioning improved.

The evidence is very uncertain about the effect of atenolol (Tenormin) on daily functioning in ME/CFS or long COVID. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (1 in all)
  • Not all results were tested against chance
See the 1 study
  1. A Case Study of Successful Application of the Principles of ME/CFS Care to an Individual with Long COVID. (2023)

    People in the study
    1 in the study
    Dose
    —
    Outcome
    energy and overall function on naltrexone
    Effect
    better (not tested)
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Overall symptoms1 study · 1 (few people) person took Atenolol (Tenormin) Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (1 in all).

Studies with no comparison group1 in the study · over 30 months (few people)

Overall symptoms improved.

The evidence is very uncertain about the effect of atenolol (Tenormin) on overall symptoms in ME/CFS or long COVID. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (1 in all)
See the 1 study
  1. A Case Study of Successful Application of the Principles of ME/CFS Care to an Individual with Long COVID. (2023)

    People in the study
    1 in the study
    Dose
    —
    Outcome
    symptom improvement over 30 months
    Effect
    better
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I

Side effects

Side effects studies reported2 kinds
Side effects studies reported, and how many studies reported each
Side effectStudies that reported it
Fatigue1 study
Worse symptoms or a flare1 study

All papers

  1. A Case Study of Successful Application of the Principles of ME/CFS Care to an Individual with Long COVID.2023 · case report · 1 in the study
    Summary

    This case study reports a 19-year-old male who developed impairment consistent with ME/CFS after SARS-CoV-2 infection. The study reports one patient; there was no comparison group, and outcomes were before-versus-after over 30 months. Treatment included physical therapy; stationary biking and running as graded activity; oral sodium chloride and lower limb compression garments; and medications/supplements: fludrocortisone, midodrine, atenolol, pyridostigmine bromide, ivabradine, clonidine, methylphenidate, fexofenadine, famotidine, cromolyn, quercetin, escitalopram, and naltrexone. The paper reports significant improvement in symptoms over 30 months. With cromolyn, peak walking heart rate fell from the 130–140 bpm range to 100–105 bpm. Stopping fexofenadine and famotidine was accompanied on more than one occasion by increased fatigue and cognitive dysfunction; stopping H1 and H2 antihistamines was associated with worsened concentration and short-term memory. Naltrexone was associated with improved energy and overall function, and the patient reported improvements with low doses of clonidine and methylphenidate. For the first 15 months after infection, he continued to have exercise intolerance, with heart rate reaching 130–150 bpm during each of two 15-min walks daily. At one year, remaining symptoms included daily fatigue; lightheadedness and headaches were infrequent. He later resumed running at 10 min four times a week, increased running by two minutes each week, and in October 2022 competed in an 8 K event. Adverse effects were reported with fludrocortisone, midodrine, atenolol, pyridostigmine bromide, and ivabradine. Limitations stated include possible spontaneous improvement and uncertainty about independent effects of interventions.

  2. Treatments for Long COVID autonomic dysfunction: a scoping review.2025 · review
    Summary

    This scoping review included 11 effectiveness studies, 11 guidelines/position statements, and 15 unpublished/ongoing studies of Long COVID autonomic dysfunction. Among comparative data, an NRCS in Italy gave fexofenadine 180 mg/day plus famotidine 40 mg/day to 14 patients and compared them with 13 who received no antihistamines; follow-up increased heart rate was 29% vs. 85% (p = 0.0063) and abdominal disorders 14% vs. 62%. An RCT of 463 patients compared SIM01 with placebo: fatigue alleviation 63% vs. 43% (OR 2.273, 95% CI 1.520–3.397), GI upset 70% vs. 54% (OR 1.995, 95% CI 1.304 to 3.051); quality of life 76.0 vs. 74.5 (p = 0.17) and physical activity p = 0.37 did not differ significantly. Any AE was 9.5% vs. 10.8%. Single-arm studies reported pre-post changes: maraviroc plus pravastatin (18), SSRIs (95; serious side effects 31.6% [30/95], mild 54.7% [52/95]), a nutraceutical (51), multicomponent treatment with salt/water/compression plus bisoprolol (32), HRV biofeedback (13), inspiratory muscle training (26), and SGB (41; vagal response 7.3% [3/41], transient hoarseness 9.8% [4/41]). Review authors state existing studies are often small and uncontrolled.

A little hope, every Sunday

New recovery stories and data-driven research on ME/CFS and long COVID. Ideas worth considering, and the evidence behind them.

Free · Unsubscribe anytime